PSP001 - A First-in-disease human PEGIFN-λ Chimera
| May 3rd,2021 Phase 1 Site Initiation Visit; |
| Date:2019-08-05 18:47:50 | Visits： |
| Prev:Feb 3rd 2021. FDA issued letter "Safe-to-proceed"; Next:July 5th,2022 complet Phase 1 SAD cohorts; |
| May 3rd,2021 Phase 1 Site Initiation Visit; |
| Date:2019-08-05 18:47:50 | Visits： |
| Prev:Feb 3rd 2021. FDA issued letter "Safe-to-proceed"; Next:July 5th,2022 complet Phase 1 SAD cohorts; |
Beijing Headquarter:
Add: A302 No.5 Kaituo Road, Haidian District, Beijing, China, 100085
Tel: +86-10-62975234
Manufacturing Facility & Laboratory:
Building No. 3, Peptide Valley, GuAn, Hebei, China
US Clinical Center:
Seattle, WA, USA
Copyright 2021 prositsole All Rights Reserved. 备案号：京ICP备19006758号-2